KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,921 ILa | +0.10% |
|
-3.08% | -13.74% |
| May. 08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Kamada Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 592M 161M 59.18B | Sales 2025 * | 665M 181M 66.52B | Capitalization | 1.1B 301M 110B |
|---|---|---|---|---|---|
| Net income 2024 * | 53M 14.44M 5.3B | Net income 2025 * | 63M 17.16M 6.3B | EV / Sales 2024 * | 1.87 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.66 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 378 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kamada Ltd.
More press releases
| 1 day | +0.10% | ||
| 1 week | -3.08% | ||
| Current month | -3.18% | ||
| 1 month | -0.88% | ||
| 3 months | -15.08% | ||
| 6 months | +8.47% | ||
| Current year | -13.74% |
1 week
1 908.00
1 948.00
1 month
1 908.002 200.00
Current year
1 872.002 338.00
1 year
1 685.002 338.00
3 years
1 309.002 338.00
5 years
1 309.004 500.00
10 years
1 160.004 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Amir London
CEO | Chief Executive Officer | 55 | 13-12-08 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
Chaime Orlev
DFI | Director of Finance/CFO | 53 | 17-12-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ishay Davidi
BRD | Director/Board Member | 62 | 19-12-23 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
David Tsur
FOU | Founder | 73 | 90-12-12 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 1,921 | +0.10% | 18,143 |
| 24-05-26 | 1,919 | +0.10% | 12,364 |
| 24-05-23 | 1,917 | -0.10% | 17,056 |
| 24-05-22 | 1,919 | -0.98% | 47,877 |
| 24-05-21 | 1,938 | -2.22% | 31,230 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 27, 2024 at 10:24 am EDT
More quotes
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.74% | 300M | |
| -1.91% | 90.28B | |
| -0.66% | 39.5B | |
| -15.83% | 31.71B | |
| +62.42% | 26.41B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -10.32% | 11.8B | |
| -45.77% | 10.95B | |
| +3.45% | 8.85B |
- Stock Market
- Equities
- KMDA Stock
